Atrial fibrillation: new Oral anticoagulants for preventing stroke and embolism
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2009 Sep 17;361(12):1139-51. Epub 2009 Aug 30. Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, non valvular, stroke, ischemic, cerebral infarction, embolic The Use of
oral direct thrombin inhibitors, dabigatran, 110 or 150 mg twice daily fixed dose
As Treatment, Chronic
Is better Than
warfarin, INR adjusted dose
To reduce at 2 years ischemic strokes (1.53% - 1.11% per year 110 - 150 mg dabigatran VS 1.69% warfarin), with similar major bleedings (2.71% - 3.36% per year) and less haemorrhagic strokes (0.10% per year dabigatran VS 0.38% warfarin)
N Engl J Med. 2011 Feb 10. [Epub ahead of print] Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, non valvular, stroke, ischemic, cerebral infarction, embolic, patients not suitable for vitamine K antagonists, warfarin The Use of
apixaban, oral factor Xa inhibitors
As Treatment, Chronic
Is better Than
aspirin
To reduce stroke or systemic embolism (1.6% per year apixaban VS 3.7% aspirin) while not increasing major bleeding (1.4% per year apixaban VS 1.2% aspirin)